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High-resolution X-ray crystallography and NMR studies by Koharudin and Gronenborn in this issue provide
new information on the mode of N-glycan recognition by a cyanobacterial agglutinin, with anti-HIV activity
pointing to the pentamannosyl core as a novel target for therapeutic intervention.In addition to its extreme genetic vari-
ability, the human immunodeficiency virus
(HIV) has evolved a number of biological
features that contribute to its notorious
ability to escape from both the innate
and adaptive immune responses. Notable
among these is the extensive glycosylation
of its major envelope glycoprotein gp 120
(120kDa), which is required for HIV infec-
tion that is mediated through interactions
with the glycoprotein CD4 on the surface
of target cells. Approximately fifty percent
of the molecular mass of gp 120 is carbo-
hydrate in the form of diverse N-glycans
(Mizuochi et al., 1988; Feizi and Larkin,
1990). Both on the natural gp120 isolated
from virus-infected lymphocytes and on a
recombinant form of the glycoprotein ex-
pressed in Chinese hamster ovary cells,
a considerable proportion of the glycans
were found to be of the oligomannose
(also termedhigh-mannose) type,whereas
the repertoire of complex-type N-glycans
was cell-type specific. The conservation
of a large population of oligomannose
N-glycans has now been confirmed in
primary isolates from geographically
diverse clades of HIV that have been pro-
duced from the direct infection of human
cells (Bonomelli et al., in press).When the observations of the heavy
glycosylation of gp 120 were first made,
we wondered whether the glycans served
to camouflage the virus in the infected
host or whether they had an influence at
particular stages of the infection process
(Feizi and Larkin, 1990). Indeed, there is
an enormous body of evidence on the
way that glycans serve to shield the gp
120 polypeptide from immune attack;
however, this topic is beyond the scope
of this commentary. We focus here on
the oligomannose N-glycans, which have
proven to be more than merely shields in
the armamentarium of the virus! HIV uses
its oligomannose N-glycans to highjack
akeyprotein of the innate immunesystem,
DC-SIGN, and gain entry into a protected
environment in dendritic cells, where
they remain available and poised to reach
the cell surface to infect bystander
T-lymphocytes (Geijtenbeek et al., 2000).
As for the host’s immune response
toward the gp 120N-glycans, interactions
with two of the innate immune proteins,
mannose-binding protein and the macro-
phage receptor, have been observed
in vitro, but a clear picture has not
emerged with regard to any protective
effects they might have in infectedpatients. An unpredicted development
has been the discovery, among broadly
neutralizing antibodies against HIV, of an
antibody, clone 2G12, which is directed
at the Mannose-9 (Man9) N-glycan (Scan-
lan et al., 2002). This antibody requires the
Mana1-2Man termini of its D1 arm
(Dunlop et al., 2010) (Figure 1A). These
findings have served to stimulate efforts
in two directions. The first is ongoing
studies to develop vaccination strategies
to generate anti-Man9 antibodies with
broadly neutralizing activities, such as
those described by Dunlop et al. (2010).
The second direction has been to estab-
lish technologies to map the specificities
of broadly neutralizing antibodies in sera
of patients that exhibit the most potent
antiviral activities (Walker et al., 2010).
There are encouraging indications with
regard to the natural occurrence of anti-
bodies, which are either directed to
protein structures dependent on N-linked
glycosylation or, as for 2G12, directly bind
to the glycans of gp120. Further develop-
ments are eagerly awaited.
Bacterial, fungal, and algal proteins
with potent antiviral activities have now
‘‘emerged’’ in the anti-HIV battlefield and
exhibit great potential applications as2011 Elsevier Ltd All rights reserved 1035
Figure 1. Chemical Structures of Man9 N-Glycan and of Related Oligomannose Derivatives Relevant to the Specificity of OAA
(A) The Man9N-glycan. The pentamannosyl core residues recognized by OAA are in red. The Mana1-2Man motifs in the D1, D2, and D3 arms at the nonreducing
end of the Man9 N-glycan are surrounded by a dotted line.
(B) The a3,a6-mannopentaose used by Koharudin and Gronenborn in the present study (Koharudin and Gronenborn, 2011).
(C) The pentamannosyl sequence with chitobiosyl core and (D) the analog lacking the chitobiosyl core, respectively. Both were used as aminopyridine-tagged
derivatives prepared by reductive amination in the Sato et al. (2007) study. The sequence suggested by these authors as the putative recognition motif for OAA is
in red.
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discussed by Koharudin and Gronenborn
(2011) in this issue of Structure, and many
of these lectins recognize the Mana1-
2Man disaccharide sequence of the D1
and D3 arms at the nonreducing end of
the Man9 N-glycan, depicted in Figure 1A.
Among these lectins are Cyanovirin-N,
a virucidal lectin originally identified in
an extract from the cyanobacterium
Nostoc ellipsosporum, and structurally
related fungal homologs. Other such lec-
tins are Scytovirin from cyanobacterium
Scytonema varium and red alga lectin Grif-
fithsin from Griffithsia sp. The structural
diversity in recognition modes may hold
promise for the clinical protection against
a wide range of HIV, each of which may
display distinct patterns of oligomannose
termini.
The structural study in this issue of
Structure by Koharudin and Gronenborn1036 Structure 19, August 10, 2011 ª2011 Eis a sequel to two previous publications
on a novel antiviral lectin, the cyanobacte-
rial Oscillatoria agardhii agglutinin (OAA).
The first was a biochemical study
addressing N-glycan recognition by OAA
from another group (Sato et al., 2007).
Using a large series of N-glycans tagged
with aminopyridine at their reducing
ends, which the authors tested in a
direct binding assay, they provided
evidence that is consistent with OAA
recognizing the pentamannosyl-chitobio-
syl core (Figure 1C). The analog lacking
the chitobiosyl core (Figure 1D) was not
bound, leading the authors to conclude
that the chitobiosyl core (GlcNAcß1-
4GlcNAc) was required for OAA binding.
The second publication on OAA was
a recent study by the Gronenborn group
(Koharudin, et al., 2011), in which they
described the first crystal structure of
OAA, revealing a novel protein fold. Theylsevier Ltd All rights reservedalso performed NMR analyses of the
binding of OAA to Man9 N-glycan
(Figure 1A) and its disaccharide compo-
nents, which identified two symmetric
carbohydrate-binding sites on OAA and
indicated that it preferentially binds to
Mana1-6Man and not to Mana1-2Man
termini or to the chitobiosyl sequence.
And in two putative models of the Man9
N-glycan interaction with OAA, the chito-
biosyl core was depicted as pointing
away from the OAA binding, and by infer-
ence unlikely to be bound by the protein.
In the present study, the authors demon-
strate, by NMR titration studies, that the
a3,a6-mannopentaose (Figure 1B), the
branched core unit of Man9 N-glycan
(Figure 1A), binds tightly toOAA (Koharudin
andGronenborn, 2011), and theyobserved
similar resonancescompared to thosewith
the full-lengthMan9N-glycan.Moreover, in
a high-resolution crystal structure of the
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pentaose, the authors could clearly see all
five mannoses and were able to delineate
specific protein-sugar contacts at the
atomic level and thus establish a critical
role in the recognition of the central beta
mannose at the branch point (Koharudin
and Gronenborn, 2011). The structure
also offers a reassuring and plausible
explanation for the variance to previous
data regarding the involvementof thechito-
biosyl core in the binding of OAA (Sato
et al., 2007), in that the aminopyridine-
tagged mannose at the reducing end of
pentamannosyl glycan that was examined
bySato et al. (2007)was in the ring-opened
form (Figure 1D).
The specificity for the pentasaccharide
core of the Man9 N-glycan represents
a new mode of carbohydrate recognition
for this group of lectins with anti-HIV
activity. What is now needed is to deter-
mine precisely the distinctive features
among the numerous lectins that conferantiviral activity. Koharudin and Gronen-
born (2011) raise the possibility of
synergistically harnessing lectins that
recognize the different motifs on the outer
regions and the core of the Man9 domain
in the ‘‘fight’’ against HIV transmission.
Once these distinctive features are deter-
mined, would it perhaps be possible to
engineer proteins with multiple binding
sites recognizing the different motifs for
use as anti-HIV drugs with enhanced
potencies? Without a doubt, there are
challenges to overcome in the ‘‘drug-
gability’’ of these microbial proteins with
respect to their immunogenicity, stability,
and delivery.REFERENCES
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